Sp1084
HOW DOES GUT MICROBIOTA DRIVE METABOLIC SYNDROME?
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
In this session we will learn about the exciting advances in mechanisms by which microbial metabolites as well can drive metabolic disorders and the pipeline of potential microbial therapeutics to treat metabolic disorders.
In this session we will learn about the exciting advances in mechanisms by which microbial metabolites as well can drive metabolic disorders and the pipeline of potential microbial therapeutics to treat metabolic disorders.
Presenter
Vanderbilt University Medical Center
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AGA Gut Microbial Metabolites as Central Regulators in Metabolic Disorders
In this session we will learn about the exciting advances in mechanisms by which microbial metabolites as well can drive metabolic disorders and the pipeline of potential microbial therapeutics to treat metabolic disorders…
